Comparison of the technical and clinical performance of the Elecsys® HBsAg II assay with the Architect®, AxSym®, and Advia® Centaur HBsAg screening assays

2010 ◽  
Vol 82 (5) ◽  
pp. 755-762 ◽  
Author(s):  
S. Louisirirotchanakul ◽  
K. Khupulsup ◽  
S. Akraekthalin ◽  
K.P. Chan ◽  
S. Saw ◽  
...  
Keyword(s):  
Clinical Performance ◽  
Screening Assays ◽  
Hbsag Screening

scholarly journals Improved Detection of Hepatitis B Virus Surface Antigen by a New Rapid Automated Assay

1999 ◽  
Vol 37 (8) ◽  
pp. 2639-2647 ◽  
Author(s):  
Bernard Weber ◽  
Anja Bayer ◽  
Peter Kirch ◽  
Volker Schlüter ◽  
Dietmar Schlieper ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
Sensitivity And Specificity ◽  
Surface Antigen ◽  
Core Antigen ◽  
B Virus ◽  
Acute Hepatitis B ◽  
Screening Assays ◽  
Hbsag Screening

The performance of hepatitis B virus (HBV) surface antigen (HBsAg) screening assays is continuously improved in order to reduce the residual risk of transfusion-associated hepatitis B. In a multicenter study, a new automated rapid screening assay, Elecsys HBsAg (Roche Diagnostics), was compared to well-established tests (Auszyme Monoclonal [overnight incubation] version B and IMx HBsAg [Abbott]). Included in the evaluation were 23 seroconversion panels; sera from the acute and chronic phases of infection; dilution series of various HBsAg standards, HBV subtypes, and S gene mutants; and isolated anti-HBV core antigen-positive samples. To challenge the specificity of the new assay, sera from HBsAg-negative blood donors, pregnant women, and dialysis and hospitalized patients and potentially cross-reactive samples were investigated. Elecsys HBsAg showed a higher sensitivity for HBsAg subtypes ad, ay, adw2, adw4, ayw1, ayw2, ayw4, and adr detection in dilution series of different standards or sera than Auszyme Monoclonal version B and/or IMx HBsAg. Acute hepatitis B was detected in 11 to 16 of 23 seroconversion panels between 2 and 16 days earlier with Elecsys HBsAg than with the alternative assays. Elecsys HBsAg and Auszyme Monoclonal version B detected HBsAg surface mutants with equal sensitivity. The sensitivity and specificity of Elecsys HBsAg were 100%. Auszyme Monoclonal version B had a 99.9% specificity, and its sensitivity was 96.6%. IMx HBsAg showed a poorer sensitivity and specificity than the other assays. In conclusion, Elecsys HBsAg permits earlier detection of acute hepatitis B and different HBV subtypes than the alternative assays. By using highly sensitive HBsAg screening assays, low-level HBsAg carriers among isolated anti-HBV core antigen-positive individuals can be detected.

578 Analytical and clinical performance of NT-proBNP immunoassay

2003 ◽  
Vol 2 (1) ◽  
pp. 125-126
Author(s):  
C PRONTERA ◽  
C PASSINO ◽  
A IERVASI ◽  
G ZUCCHELLI ◽  
A CLERICO ◽  
...  
Keyword(s):  
Clinical Performance

Use of Receiver Operating Characteristic (ROC) Curves to Evaluate Computer Confidence Threshold and Clinical Performance in the Diagnosis of Appendicitis

1978 ◽  
Vol 17 (03) ◽  
pp. 157-161 ◽  
Author(s):  
F. T. De Dombal ◽  
Jane C. Horrocks
Keyword(s):  
Receiver Operating Characteristic ◽  
Operating Characteristic ◽  
Clinical Performance ◽  
Roc Curves ◽  
Final Diagnosis ◽  
Confidence Threshold ◽  
Computer Aided ◽  
Computer Confidence ◽  
Overall Performance ◽  
Receiver Operating

This paper uses simple receiver operating characteristic (ROC) curves (i) to study the effect of varying computer confidence of threshold levels and (ii) to evaluate clinical performance in the diagnosis of acute appendicitis. Over 1300 patients presenting to five centres with abdominal pain of short duration were studied in varying detail. Clinical and computer-aided diagnostic predictions were compared with the »final« diagnosis. From these studies it is concluded the simplistic setting of a 50/50 confidence threshold for the computer program is as »good« as any other. The proximity of a computer-aided system changed clinical behaviour patterns; a higher overall performance level was achieved and clinicians performance levels became associated with the »mildly conservative« end of the computers ROC curve. Prior forecasts of over-confidence or ultra-caution amongst clinicians using the computer-aided system have not been fulfilled.

The Role of Stent Design and Polymers in Safety Outcomes – A Review

2012 ◽  
Vol 8 (1) ◽  
pp. 63
Author(s):  
Carlo Zivelonghi ◽  
Giulia Geremia ◽  
Michele Pighi ◽  
Flavio Ribichini ◽  
◽  
...  
Keyword(s):  
Clinical Performance ◽  
Drug Carrier ◽  
Chemical Properties ◽  
Vascular Wall ◽  
Radial Force ◽  
Vascular Trauma ◽  
Polymer Composition ◽  
Drug Eluting Stent ◽  
Stent Design ◽  
Drug Elution

Each component of a drug-eluting stent (DES) contributes to the safety of the device. Continuous efforts are being dedicated to the search of the optimal compromise between facility of use, safety and long-term efficacy. Shorter balloons reduce the vascular trauma beyond the stent struts; the metallic composition of the stent platform and the platform itself interact with the vascular wall in a long-lasting equilibrium between radial force, vessel patency and reparative cellular regrowth. The modality of drug elution is largely regulated by the chosen drug carrier, rather than by the chemical properties of the drug itself. Drug elution can be accomplished by permanent polymers that remain in the vessel wall forever, by biodegradable polymers that leave the naked metallic structure behind after their complete absorption, or even by direct release of the drug from stent reservoirs. The clinical performance of DESs has been exhaustively assessed in a large number of studies that have showed rapid and continuous improvements, from the first-generation DESs to the latest devices, based on substantial changes in stent design and polymer composition.

Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry

2020 ◽  
Vol 22 (2) ◽  
pp. 94-100 ◽  
Author(s):  
Bernardo Cortese ◽  
Luca Testa ◽  
Gaetano Di Palma ◽  
Tay M. Heang ◽  
Irene Bossi ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Clinical Performance ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document